Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment.

The Journal of Pediatrics
Melissa J Frei-JonesGeorge R Buchanan

Abstract

To describe emergency department (ED) management of older children with sickle cell disease (SCD) experiencing a vaso-occlusive episode (VOE) and factors associated with disposition and ED return. We retrospectively reviewed ED visits of children age >/=8 years with SCD over the course of 1 year. Data were collected from the electronic medical record and the SCD database. VOE was diagnosed 279 times in 105 patients; 45 of the patients had 1 ED visit, 25 had 2 ED visits, and 16 had >/=5 ED visits. The overall admission rate was 178/279 (64%), 166 on the first ED visit and 12 on a return visit within 72 hours. Use of home opioids, duration of VOE, and hemoglobin concentration were not associated with disposition. Discharge after 2 doses of intravenous (IV) morphine occurred in 33 patients. Pain relief after 1 dose, using a FACES scale of 1 to 5, differed significantly between the admitted patients and the discharged patients (1.1 vs 2.5; P < .0001). Suboptimal pain relief after 1 dose of IV morphine was associated with admission from the ED. Further investigation of pain relief, using validated pain assessment scales, as an outcome in VOE management is warranted.

References

Jul 4, 1991·The New England Journal of Medicine·O S PlattT R Kinney
Dec 12, 1991·The New England Journal of Medicine
Jun 9, 1994·The New England Journal of Medicine·O S PlattP P Klug
Aug 1, 1996·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·B L LopezL Urbanski
Sep 18, 1997·Journal of Pain and Symptom Management·B S ShapiroG Heidrich
Feb 24, 1998·Palliative Medicine·R D Hain
Aug 4, 1999·The Journal of Emergency Medicine·R SilbergleitR M McNamara
Feb 15, 2002·Journal of Pain and Symptom Management·Linda S FranckElliott Vichinsky
Jul 4, 2002·American Journal of Surgery·Abdulrahman Saleh Al-MulhimAbdulmohsen Abdulla Al-Suwaiygh
Apr 8, 2003·Journal of Pediatric Hematology/oncology·Eufemia JacobLori Styles
Oct 4, 2003·Blood·Kim Smith-WhitleyKwaku Ohene-Frempong
Feb 7, 2004·Blood·Charles T QuinnGeorge R Buchanan
Jul 20, 2004·The American Journal of Emergency Medicine·Jennifer I ChapmanBema K Bonsu
Jan 25, 2005·The American Journal of Emergency Medicine·Bret P NelsonAdam J Singer
Feb 3, 2007·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Karin HesselgardPeter Reinstrup

❮ Previous
Next ❯

Citations

Apr 24, 2012·Drugs·Emily Riehm Meier, Jeffery L Miller
Aug 26, 2009·The Journal of Emergency Medicine·William T ZempskyNeil L Schechter
Mar 2, 2011·Pediatric Blood & Cancer·Julie A WolfsonMichele D Kipke
Jan 13, 2011·Pediatric Blood & Cancer·Julie A WolfsonMichele D Kipke
Oct 21, 2016·Pediatric Blood & Cancer·Jennifer HorstEvan D Kharasch
Jul 16, 2013·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Martin Schiavenato, Ofelia Alvarez
Jul 23, 2011·Acta Haematologica·Oula Abdullah Najim, Mea'ad Kadhum Hassan
Feb 11, 2016·World Journal of Clinical Pediatrics·Lorenzo IughettiDonatella Venturelli
Mar 30, 2013·Clinical Trials : Journal of the Society for Clinical Trials·Carlton D DampierUNKNOWN Sickle Cell Disease Clinical Research Network (SCDCRN)
Feb 18, 2021·Critical Care Nursing Quarterly·Nancy CregoPaula Tanabe
May 14, 2009·Current Opinion in Supportive and Palliative Care

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.